{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-03T17:09:34.632324+00:00","company":{"ticker":"AGIO","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC."},"pagination":{"limit":100,"returned":3,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"34b058a6c5d7cef4186a4d98bdaf0205b83f0272","cik":1439222,"ticker":"AGIO","company_name":"AGIOS PHARMACEUTICALS, INC.","filed_at":"2026-04-29T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$99.1 million","period_text":"the quarter ended March 31, 2026","report_date":"2026-04-29","result_type":"reported_results","revenue_text":null},"claim":"AGIOS PHARMACEUTICALS, INC. reported the quarter ended March 31, 2026 results: net income $99.1 million.","evidence_excerpt":"For the quarter ended March 31, 2026, net loss was $99.1 million, compared to net loss of $89.3 million for the quarter ended March 31, 2025.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001439222-26-000071","anchor_url":"https://secwatch.observer/filing/0001439222-26-000071#claim-34b058a6c5d7cef4186a4d98bdaf0205b83f0272","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000071/0001439222-26-000071-index.htm"},{"fact_type":"executive_change","fact_key":"10d5da77de","cik":1439222,"ticker":"AGIO","company_name":"AGIOS PHARMACEUTICALS, INC.","filed_at":"2025-02-13T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-02-28","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"David P. Schenkein, M.D. resigned as Director at AGIOS PHARMACEUTICALS, INC..","evidence_excerpt":"On February 10, 2025, David P. Schenkein, M.D., notified Agios Pharmaceuticals, Inc. (the “Company”) of his decision to resign from the Board of Directors of the Company (the “Board”), effective February 28, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-25-025524","anchor_url":"https://secwatch.observer/filing/0001193125-25-025524#claim-10d5da77de","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1439222/000119312525025524/0001193125-25-025524-index.htm"},{"fact_type":"earnings_release","fact_key":"445c115425a11a5b82d1639a12b22a496d351fdb","cik":1439222,"ticker":"AGIO","company_name":"AGIOS PHARMACEUTICALS, INC.","filed_at":"2024-05-02T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the first quarter ended March 31, 2024","report_date":"2024-05-02","result_type":"reported_results","revenue_text":"$8.2 million"},"claim":"AGIOS PHARMACEUTICALS, INC. reported the first quarter ended March 31, 2024 results: revenue $8.2 million.","evidence_excerpt":"RISE UP Study in Sickle Cell Disease, ACTIVATE-KIDS and ACTIVATE KIDS-T in Pediatric PK Deficiency, All Expected by End of 2025 – – PYRUKYND® (Mitapivat) Net Revenue of $8.2 Million in Q1; Cash, Cash Equivalents and Marketable Securities of $714.3 Million as of March 31, 2024 – CAMBRIDGE, Mass., May 2, 2024 – Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001439222-24-000067","anchor_url":"https://secwatch.observer/filing/0001439222-24-000067#claim-445c115425a11a5b82d1639a12b22a496d351fdb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000067/0001439222-24-000067-index.htm"}]}